Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Wave Life Sci Ord Sh (NQ: WVE ) 6.130 +0.560 (+10.05%) Streaming Delayed Price Updated: 1:22 PM EDT, Jul 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Wave Life Sci Ord Sh < Previous 1 2 Next > Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease June 25, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing June 12, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference May 30, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer May 09, 2024 Appointment builds on Wave’s recent progress advancing innovative genetic targets, such as INHBE, and continues to add significant experience to accelerate the rapid identification and translation of... From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 May 02, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) April 30, 2024 Proof-of-mechanism data for WVE-006 in individuals with AATD remain on track for 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing April 23, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at Upcoming Investor Conferences March 27, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 06, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024 February 28, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy February 27, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Sarepta Therapeutics Inc.: Why it's a rising gene therapy star January 23, 2024 Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. Via MarketBeat Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones January 08, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy December 15, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares December 07, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants December 06, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency December 06, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference November 22, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023 November 03, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day September 28, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference September 25, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 06, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day” September 05, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update August 03, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023 July 27, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes June 26, 2023 From Wave Life Sciences USA, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
